Shashidhar Kori

Dr. Kori has more than 30 years of research and drug development experience in Neurosciences. Prior to his position at Exalys he was the Chief Medical Officer at Trigemina Inc. Previously he was CMO at ATI, responsible for clinical research, clinical outcomes, and regulatory submissions in the United States and in Europe. Prior to Joining ATI he was VP of Clinical Development and Medical Affairs at Allergan Inc. Prior to that as the VP of Clinical development and Medical Affairs at MAP Pharmaceuticals he built a Medical Affairs department from scratch, helped submit a NDA, multiple INDs, ran Clinical Operations and oversaw an active publication strategy. Before that he was Senior Director of Clinical Development at GlaxoSmithKline.

Prior to joining GSK Dr. Kori had 24 years of Academic Medicine experience at major universities across the country including Memorial Sloan Kettering Cancer Center, Case Western Reserve University, H. Lee Moffitt Cancer Center & Research Institute, and Duke University. Dr. Kori has extensive experience in clinical patient care, teaching, research, and administration. He has also served as President or Board of Director or Committee Chair of several national professional societies, delivered invited lectures in more than a dozen countries, chaired several national professional seminars and symposia, acted as Visiting Professor at 10 universities, sat on Editorial Boards or served as Medical Reviewer for 7 professional journals.